when was bpc 157 created BPC-157 Peptide (Pentadecapeptide) 5mg, 10mg & 15mg BPC-157 Injectable Peptide for Healing

Unfortunately, there is no evidence that any of these agents modify the underlying pathophysiology of peripheral neuropathy.(16) Studies have shown that high doses of methylcobalamin improved nerve conduction in streptozotocin-diabetic rats.(17) This was again demonstrated in experimental acrylamide neuropathy, where high doses of methylcobalamin were associated with a significant increase in the rate of motor nerve fibre regeneration.(18) This may be the mechanism through which methylcobalamin acts to modify and treat the underlying pathophysiology of peripheral neuropathy

My rule of thumb is if the latest and most current B12 result is above the defined acceptable range then it is advisable to recommend a reduction in the frequency of the intervention

The ACO meets any of the grounds for ACO termination set forth at 425.218(b)

Dosage may be more precise as well